FrancophonIA/ELRC3.0 huggingface dataset:
English: Ref. EMEA/CHMP/194790/2009 EMEA/H/A-29/991
Estonian: viide EMEA/CHMP/194665/2009 EMEA/H/A-29/991
English: Prof Michal Pirożynski (Poland)
Estonian: prof Michal Pirożynski (Poola)
English: Dr Gonzalo Calvo Rojas (Spain)
Estonian: dr Gonzalo Calvo Rojas (Hispaania)
English: Company responses provided on: 30 May 2008, 20 October 2008 Opinion date:
Estonian: Firma vastuste laekumise kuupäevad: 30. mai 2008, 20. oktoober 2008 Arvamuse esitamise kuupäev:
English: What is Sanohex?
Estonian: Mis on Sanohex?
English: This is a procedure when one Member State (the ‘reference Member State', in this instance Sweden) assesses a medicine with a view of granting a marketing authorisation that will be valid in this country as well as in other member states (the ‘concerned Member States', in this instance Austria, Germany, Ireland and Spain).
Estonian: Tegemist on menetlusega, mille käigus üks liikmesriik (viiteliikmesriik, käesoleval juhul Rootsi) hindab ravimit eesmärgiga anda sellele müügiluba, mis kehtib nii selles riigis kui ka teistes liikmesriikides (asjaomastes liikmesriikides, praegusel juhul Austrias, Hispaanias, Iirimaal ja Saksamaal).
English: Sanohex is used to relieve symptoms, and its use should not delay the use of inhaled steroids.
Estonian: Sanohexi kasutatakse sümptomite leevendamiseks ning selle kasutamisel ei tohiks inhaleeritavate steroidide manustamisega viivitada.
English: Hexal AG submitted Sanohex to the Swedish medicines regulatory agency for a decentralised procedure on 5 December 2006.
Estonian: Hexal AG esitas Rootsi ravimiametile 5. detsembril 2006 taotluse Sanohexi käsitleva detsentraliseeritud menetluse rakendamiseks.
English: Sanohex is a ‘generic medicine'.
Estonian: Sanohex on geneeriline ravim.
English: Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Sanohex outweigh its risks, and that therefore the marketing authorisation for Sanohex should be granted in all concerned member states.
Estonian: Praeguseks kättesaadavate andmete hindamise ning komitees toimunud teadusliku arutelu põhjal jõudis inimravimite komitee järeldusele, et Sanohexist saadav kasu kaalub üles sellega kaasnevad riskid ning seetõttu tuleb kõikides asjaomastes liikmesriikides anda ravimile müügiluba.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Sanohex outweigh its risks, and that the marketing authorisation can be granted in Sweden as well as in the following Member States of the European Union: Austria, Germany, Ireland and Spain.
Estonian: Ameti inimravimite komitee on jõudnud otsusele, et Sanohexist saadav kasu kaalub üles sellega kaasnevad riskid ning ravimile võib anda müügiloa Rootsis ja ka järgmistes Euroopa Liidu liikmesriikides: Austria, Hispaania, Iirimaa ja Saksamaa.
English: The European Medicines Agency (EMEA) has completed a referral procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Sanohex.
Estonian: Euroopa Ravimiamet (EMEA) on pärast Euroopa Liidu liikmesriikide vahelise lahkarvamuse ilmnemist lõpetanud esildise menetlemise, milles käsitletakse ravimile Sanohex müügiloa andmist.
English: The grounds for the referral were concerns regarding that there was not enough data showing that Sanohex is equivalent to the reference medicine.
Estonian: Esildise aluseks olid kahtlused seoses sellega, et Sanohexi võrdväärsuse kohta võrdlusravimiga puuduvad piisavad andmed.
English: This means that Sanohex is similar to a ‘reference medicine' already authorised in the European Union (EU) called Sultanol inhaler.
Estonian: See tähendab, et Sanohex sarnaneb Euroopa Liidus juba müügiloa saanud inhaleeritava võrdlusravimiga Sultanol.
English: Sanohex is a medicine in a pressurised inhaler that contains salbutamol as active substance.
Estonian: Sanohex on survestatud inhalaatoris turustatav ravim, mis sisaldab toimeainena salbutamooli.
English: Sanohex is used to treat the breathing difficulties caused by asthma and chronic obstructive pulmonary disease (COPD).
Estonian: Sanohexi kasutatakse astmast ja kroonilisest obstruktiivsest kopsuhaigusest tingitud hingamisraskuste raviks.
English: When given by inhalation as in Sanohex, salbutamol directly activates the beta2-receptors in the respiratory system.
Estonian: Kui salbutamooli manustatakse inhaleerimise teel, nagu Sanohexi puhul, aktiveerib see vahetult hingamiselundkonna β2-retseptorid.
English: Why was Sanohex reviewed?
Estonian: Mis oli Sanohexi läbivaatamise põhjus?
English: Questions and answers on the referral for Sanohex salbutamol, metered dose aerosol inhaler, 100 μg/dose
Estonian: Teave järgmise ravimi esildise kohta: Sanohex, mis sisaldab annuse kohta 100 μg salbutamooli ja mida manustatakse aerosoolina dosaatorinhalaatori abil
English: 4 (4 x 1) pre-filled syringes (multipack)
Estonian: 4 (4 x 1) süstlit (mitmikpakend)
English: 1 pre-filled syringe
Estonian: Tugevus Ravimvorm
English: 0.5 ml (40000 IU/ml) 6 (6 x 1) pre-filled syringes (multipack)
Estonian: 6 (6 x 1) süstlit (mitmikpakend)
English: 1.0 ml (40000 IU/ml) 4 (4 x 1) pre-filled syringes (multipack)
Estonian: Nõelaklapiga 1,0 ml intravenoosne kasutus süstel (klaas) (10000 IU/ml)
English: 1 g / 1 g Powder for concentrate for solution for infusion
Estonian: 1 g / 1 g
English: (Invented) name Strength Pharmaceutical form
Estonian: Ravimvorm Manustamistee Sisepakendi iseloomustus
English: The European Commission granted a marketing authorisation valid throughout the European Union for Izba on 20 February 2014.
Estonian: Euroopa Komisjon andis Izba müügiloa, mis kehtib kogu Euroopa Liidus, 20. veebruaril 2014.
English: What measures are being taken to ensure the safe and effective use of Izba?
Estonian: Mis meetmed võetakse, et tagada Izba ohutu ja efektiivne kasutamine?
English: The full EPAR for Izba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Izba kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Why is Izba approved?
Estonian: Miks Izba heaks kiideti?
English: In patients taking Izba, the average eye pressure (measured at 8 am in the morning) was 19.4, 19.3 and 19.2 mmHg following 2 weeks, 6 weeks and 3 months of treatment, respectively, which matched the pressure seen at similar time points in patients taking Travatan (19.5, 19.3 and 19.3 mmHg).
Estonian: Izbat saanud patsientidel oli keskmine silmasiserõhk (mõõdetuna kell 8 hommikul) pärast 2nädalast, 6-nädalast ja 3-kuulist ravikuuri vastavalt 19,4, 19,3 ja 19,2 mmHg ning need näitajad vastasid Travatani saanud patsientidel samades ajapunktides mõõdetutele (19,5, 19,3 ja 19,3 mmHg).
English: By lowering the pressure, Izba reduces the risk of damage.
Estonian: Rõhu alandamisega vähendab Izba kahjustuste riski.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Izba's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Izba kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: What is Izba and what is it used for?
Estonian: Mis on Izba ja milleks seda kasutatakse?
English: It is not intended to provide practical advice on how to use Izba.
Estonian: Hindamisaruandes ei anta Izba kasutamise praktilisi nõuandeid.
English: Other information about Izba
Estonian: Muu teave Izba kohta
English: It can also be used in children from 3 years of age who have ocular hypertension or childhood glaucoma.
Estonian: Ravimit tohib kasutada ka vähemalt 3-aastastel lastel, kellel on okulaarne hüpertensioon või lapseea glaukoom.
English: Both medicines were given as one drop in the affected eye once a day, in the evening.
Estonian: Mõlemat ravimit manustati ühe tilgana haigesse silma üks kord ööpäevas õhtuti.
English: Izba acts in the same way and increases the flow of fluid out of the eye.
Estonian: Izbal on samasugune toime ja see suurendab vedeliku väljavoolu silmast.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Izba have been included in the summary of product characteristics and the package leaflet.
Estonian: Izba ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The safety profile of Izba seemed more favourable than that of the higher-strength solution, as side effects were less frequent with Izba.
Estonian: Izba ohutusprofiil näis olevat tugevama lahuse ohutusprofiilist soodsam, sest Izba kasutamisel esines harvem kõrvalnähte.
English: How is Izba used?
Estonian: Kuidas Izbat kasutatakse?
English: Evidence from studies with Izba in adults and with Travatan in children has also been used to work out the effectiveness of Izba in children.
Estonian: Izbat saanud täiskasvanute ja Travatani saanud laste uuringute tõendeid kasutati ka lastel Izba efektiivsuse väljaselgitamiseks.
English: It was calculated that Izba used in children would result in a similar reduction in pressure.
Estonian: Arvutati, et Izba kasutamine lastel vähendaks silmarõhk samalaadsel määral.
English: What are the risks associated with Izba?
Estonian: Mis riskid Izbaga kaasnevad?
English: The CHMP noted that Izba 30 microgram/ml is as effective as the 40 microgram/ml solution of travoprost.
Estonian: Komitee märkis, et Izba 30 μg/ml travoprosti lahus on sama efektiivne kui 40 μg/ml lahus.
English: Izba (30 microgram/ml) has been investigated in a main study involving 864 patients with open-angle glaucoma or ocular hypertension, whose average eye pressure was 27 mmHg.
Estonian: Izba 30 μg/ml silmatilgalahust uuriti põhiuuringus, milles osales 864 avatud nurga glaukoomi või okulaarse hüpertensiooniga patsienti, kelle keskmine silmasiserõhk oli 27 mmHg.
English: In the study of children with glaucoma or ocular hypertension given Travatan, the average eye pressure was reduced by around 27% after 12 weeks.
Estonian: Glaukoomiga või okulaarse hüpertensiooniga laste uuringus, kus patsientidele manustati Travatani, vähenes silmarõhk 12 nädala järel ligikaudu 27% võrra.
English: This is a summary of the European public assessment report (EPAR) for Izba.
Estonian: See on ravimi Izba Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Izba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Izbaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Izba contains the active substance travoprost.
Estonian: Izba sisaldab toimeainena travoprosti.
English: Izba is an eye-drop solution that is used to reduce intraocular pressure (pressure inside the eye) in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) and in adults with ocular hypertension (when the pressure in the eye is higher than normal).
Estonian: Izba on silmatilgalahus, mida kasutatakse silma siserõhu vähendamiseks täiskasvanud patsientidel, kellel on avatud nurga glaukoom (haigus, mille korral silma siserõhk suureneb, sest silmast ei eritu vedelikku) või okulaarne hüpertensioon (silma siserõhk on normaalsest suurem).
English: The dose is one drop of Izba in the affected eye(s) once a day, preferably in the evening.
Estonian: Annus on üks tilk Izbat haigesse silma või haigetesse silmadesse üks kord ööpäevas, eelistatavalt õhtul.
English: The active substance in Izba, travoprost, is a prostaglandin analogue (a man-made version of a prostaglandin, substances naturally found in the body).
Estonian: Izba toimeaine travoprost on prostaglandiini analoog (loodusliku prostaglandiini sünteetiline variant).
English: For practical information about using Izba, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Izba kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: An eye-drop solution containing travoprost at a concentration of 40 microgram/ml has been already authorised in the EU as Travatan since 2001.
Estonian: Travoprosti sisaldaval 40 μg/ml silmatilgalahuse kontsentraadil on ELis müügiluba ravimina Travatan alates 2001. aastast.
English: For the full list of all side effects and restrictions, see the package leaflet.
Estonian: Izba kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What benefits of Izba have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Izba kasulikkus?
English: The most common side effect with Izba (which may affect more than 1 in 10 people) is ocular hyperaemia (increased blood supply to the eye, leading to eye irritation and redness)
Estonian: Izba kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on okulaarne hüpereemia (suurenenud verevool silma, mis põhjustab silma punetust ja silmaärritust).
English: When pressure in the eye is raised, it can cause damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Estonian: Silma suurenenud siserõhk võib kahjustada võrkkesta (silma tagaosas asuv valgustundlik kelme) ja silmanärvi, mille kaudu liiguvad närvisignaalid silmast ajju.
English: How does Izba work?
Estonian: Kuidas Izba toimib?
English: Izba is available as an eye-drop solution (30 microgram/ml) and can only be obtained with a prescription.
Estonian: Izba on retseptiravim ja seda turustatakse silmatilgalahusena (30 μg/ml).
English: Izba is expected to be effective and safe in children from 3 years of age, based on adult studies and a study of 40 microgram/ml travoprost solution in children.
Estonian: Täiskasvanute uuringute põhjal ja uuringu alusel, kus lastele manustati 40 μg/ml lahust, eeldatakse, et Izba on vähemalt 3-aastastel lastel efektiivne ja ohutu.
English: The study showed that Izba was as effective as Travatan at reducing pressure in the eye following 2 weeks, 6 weeks and 3 months of treatment.
Estonian: Uuring tõendas, et 2 nädalat, 6 nädalat ja 3 kuud manustatud Izba vähendas silmasiserõhku sama efektiivselt kui Travatan.
English: Date of first authorisation: 28 September 2012 Date of latest renewal: 19 July 2017
Estonian: Müügiloa esmase väljastamise kuupäev: 28. september 2012 Müügiloa viimase uuendamise kuupäev: 19. juuli 2017
English: You can inhale this medicine any time before or after food or drink.
Estonian: Seda ravimit võib sisse hingata igal ajal enne või pärast söömist või joomist.
English: If you forget to inhale a dose, take one as soon as possible.
Estonian: Kui te unustate annuse sisse hingamata, tehke seda niipea kui võimalik.
English: If you use more Seebri Breezhaler than you should If you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit.
Estonian: Kui te kasutate Seebri Breezhalerit rohkem kui ette nähtud Kui te olete sisse hinganud liiga palju seda ravimit või keegi teine kasutab kogemata teie kapsleid, peate otsekohe ühendust võtma oma arstiga või pöörduma lähima haigla erakorralise meditsiini osakonda.
English: • Seebri Breezhaler capsules must always be stored in the blister card and only removed immediately before use.
Estonian: • Seebri Breezhaleri kapsleid peab alati hoidma blisterpakendis ja eemaldama alles vahetult enne kasutamist.
English: How to store Seebri Breezhaler Contents of the pack and other information
Estonian: Kuidas Seebri Breezhalerit säilitada Pakendi sisu ja muu teave
English: How long to continue your treatment with Seebri Breezhaler - Keep using this medicine for as long as your doctor tells you.
Estonian: Kui kaua peab jätkama ravi Seebri Breezhaleriga - Jätkake selle ravimi kasutamist senikaua, kui arst soovitab.
English: Seebri Breezhaler 44 micrograms once daily can be safely used in all age and body weight groups.
Estonian: Seebri Breezhalerit annuses 44 mikrogrammi üks kord ööpäevas võib ohutult kasutada kõikides vanuse- ja kehakaalu rühmades.
English: During treatment with Seebri Breezhaler, stop taking this medicine and tell your doctor immediately: - if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Seebri Breezhaler (signs of bronchospasm).
Estonian: Ravi ajal Seebri Breezhaleriga, lõpetage selle ravimi kasutamine ning teavitage otsekohe oma arsti sellest: - kui teil tekib vahetult pärast Seebri Breezhaleri kasutamist pingetunne rindkeres, köha, vilistav hingamine või hingeldus (bronhospasmi nähud).
English: 2) Reports have been received from post-approval marketing experience in association with the use of Seebri Breezhaler.
Estonian: 2) Teated on kogutud turuletulekujärgselt seoses Seebri Breezhaleri kasutamisega.
English: The recommended dose is the inhalation of the content of one capsule once daily using the Seebri Breezhaler inhaler.
Estonian: Annustamine Soovitatav annus on ühe kapsli sisu inhalatsioon üks kord päevas Seebri Breezhaler inhalaatorist.
English: The absolute bioavailability of glycopyrromium inhaled via Seebri Breezhaler was estimated to be about 45% of the delivered dose.
Estonian: Seebri Breezhaleri kaudu inhaleeritud glükopürrooniumi absoluutne biosaadavus oli hinnanguliselt umbes 45%.
English: The capsules must be administered only using the Seebri Breezhaler inhaler (see section 6.6).
Estonian: Kapslite manustamiseks tohib kasutada ainult Seebri Breezhaler inhalaatorit (vt lõik 6.6).
English: What Seebri Breezhaler looks like and contents of the pack Seebri Breezhaler 44 micrograms inhalation powder, hard capsules are transparent and orange and contain a white powder.
Estonian: Kuidas Seebri Breezhaler välja näeb ja pakendi sisu Seebri Breezhaler 44 mikrogrammi inhalatsioonipulbri kõvakapslid on oranžid ja läbipaistvad ning sisaldavad valget pulbrit.
English: Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Seebri Breezhaler and to contact their doctor immediately should any of these signs or symptoms develop.
Estonian: Patsiente tuleb teavitada ägeda kitsa nurga glaukoomi sümptomitest ning juhendada, et ükskõik millise nimetatud sümptomi tekkimisel tuleb otsekohe lõpetada Seebri Breezhaleri kasutamine ning võtta ühendust arstiga.
English: In clinical studies with Seebri Breezhaler, paradoxical bronchospasm was not observed.
Estonian: Seebri Breezhaleri kliinilistes uuringutes ei täheldatud paradoksaalset bronhospasmi.
English: Seebri Breezhaler once daily has also shown a statistically significant effect on health-related quality of life measured using the St. George's Respiratory Questionnaire (SGRQ).
Estonian: Üks kord ööpäevas manustatava Seebri Breezhaleri puhul on näidatud ka statistiliselt olulist mõju tervisega seotud elukvaliteedile, mida hinnati SGRQ (St. George's Respiratory Questionnaire) küsimustiku põhjal.
English: The long duration of action can be partly attributed to sustained concentrations of active substance in the lung as reflected by the prolonged terminal elimination half-life of glycopyrronium after inhalation via the Seebri Breezhaler inhaler in contrast to the half life after intravenous administration (see section 5.2).
Estonian: Pikk toime kestus on osaliselt tingitud toimeaine püsivast kontsentratsioonist kopsudes, mida näitab glükopürrooniumi pikk terminaalne eliminatsiooni poolväärtusaeg pärast inhalatsiooni Seebri Breezhaler inhalaatorist erinevalt veenisisese manustamise järgsest poolväärtusajast (vt lõik 5.2).
English: The European Medicines Agency has waived the obligation to submit the results of studies with Seebri Breezhaler in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet ei kohusta esitama Seebri Breezhaleriga läbi viidud uuringute tulemusi laste kõikide alarühmade kohta KOKi korral (teave lastel kasutamise kohta: vt lõik 4.2).
English: Glycopyrronium should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.
Estonian: Seebri Breezhalerit tohib raseduse ajal kasutada ainult juhul, kui oodatav kasu patsiendile õigustab võimalikku riski lootele.
English: This includes medicines similar to Seebri Breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium (so called anticholinergics).
Estonian: See kehtib ka Seebri Breezhaleriga sarnaste ravimite kohta, mida kasutatakse teie kopsuhaiguse raviks, nagu ipratroopium, oksitroopium või tiotroopium (niinimetatud antikolinergilised ravimid).
English: - When you start a new pack, use the new Seebri Breezhaler inhaler that is supplied in the pack.
Estonian: - Kui alustate uue pakendi kasutamist, kasutage pakendis olevat uut Seebri Breezhaler inhalaatorit.
English: How to inhale Seebri Breezhaler - In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder.
Estonian: Kuidas Seebri Breezhalerit sisse hingata - Sellest pakendist leiate inhalaatori ja kapslid (blistrites), mis sisaldavad ravimit inhaleeritava pulbrina.
English: What Seebri Breezhaler is and what it is used for What you need to know before you use Seebri Breezhaler How to use Seebri Breezhaler Possible side effects
Estonian: Mis ravim on Seebri Breezhaler ja milleks seda kasutatakse Mida on vaja teada enne Seebri Breezhaleri kasutamist Kuidas Seebri Breezhalerit kasutada Võimalikud kõrvaltoimed
English: Following oral inhalation using the Seebri Breezhaler inhaler, glycopyrronium was rapidly absorbed and reached peak plasma levels at 5 minutes post dose.
Estonian: Pärast suukaudset inhalatsiooni Seebri Breezhaler inhalaatorist imendus glükopürroonium kiiresti ja saavutas maksimaalse plasmakontsentratsiooni 5 minutit pärast annuse manustamist.
English: The co-administration of Seebri Breezhaler with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Estonian: Seebri Breezhaleri manustamist koos teiste antikolinergilisi aineid sisaldavate ravimitega ei ole uuritud ning seetõttu ei ole koosmanustamine soovitatav.
English: Seebri Breezhaler 44 micrograms once daily provided consistently statistically significant improvement in lung function (forced expiratory volume in one second, FEV1, forced vital capacity, FVC, and inspiratory capacity, IC) in a number of clinical studies.
Estonian: Seebri Breezhaler 44 mikrogrammi üks kord ööpäevas viis mitmes kliinilises uuringus kopsufunktsiooni (ühe sekundi forsseeritud ekspiratoorne maht [FEV1], forsseeritud vitaalkapatsiteet [FVC] ja inspiratoorne kapatsiteet [IC]) püsivalt statistiliselt olulise paranemiseni.
English: Seebri Breezhaler should be used with caution in patients with narrow-angle glaucoma or urinary retention.
Estonian: Seebri Breezhalerit peab ettevaatlikult kasutama patsientidel, kellel esineb kitsa nurga glaukoom või uriinipeetus.
English: In a 3-week study where exercise tolerance was tested via cycle ergometer at submaximal (80%) workload (submaximal exercise tolerance test), Seebri Breezhaler, dosed in the morning, reduced dynamic hyperinflation and improved the length of time exercise could be maintained from the first dose onwards.
Estonian: 3-nädalases uuringus, kus koormustaluvust hinnati veloergomeetri abil submaksimaalsel (80%) koormusel (submaksimaalne koormustaluvuse test), vähenes hommikul manustatud Seebri Breezhaleri toimel dünaamiline hüperinflatsioon ja paranes koormustaluvuse aeg alates esimesest annusest.
English: What Seebri Breezhaler contains - The active substance is glycopyrronium bromide.
Estonian: Mida Seebri Breezhaler sisaldab - Toimeaine on glükopürrooniumbromiid.
English: Seebri Breezhaler contains lactose
Estonian: Seebri Breezhaler sisaldab laktoosi